The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis - PubMed (original) (raw)
The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis
M W Dünser et al. Anesth Analg. 2001 Jul.
Abstract
We retrospectively investigated the effects of continuous arginine vasopressin (AVP) infusion on systemic hemodynamics, acid/base status, and laboratory variables in patients (mean age [mean +/- SD]= 66.3 +/- 10.1 yr) with catecholamine-resistant septic (n = 35) or postcardiotomy shock (n = 25). Hemodynamic and acid/base data were obtained before; 30 min after; and 1, 4, 12, 24, 48, and 72 h after the start of AVP infusion. Laboratory examinations were recorded before and 24, 48, and 72 h after the start of AVP infusion. For statistical analysis, a mixed-effects model was used. The overall intensive care unit mortality was 66.7%. AVP administration caused a significant increase in mean arterial pressure (+29%) and systemic vascular resistance (+56%), accompanied by a significant decrease in heart rate (-24%) and mean pulmonary arterial pressure (-11%) without any change in stroke volume index. Norepinephrine requirements could be reduced by 72% within 72 h. During AVP infusion, a significant increase in liver enzymes and total bilirubin concentration and a significant decrease in platelet count occurred. Arginine vasopressin was effective in reversing systemic hypotension. However, adverse effects on gastrointestinal perfusion and coagulation cannot be excluded.
Implications: In this retrospective analysis, the influence of a continuous infusion of an endogenous hormone (arginine vasopressin) on systemic hemodynamics and laboratory variables was assessed in patients with vasodilatory shock unresponsive to conventional therapy. Arginine vasopressin was effective in reversing systemic hypotension. However, adverse effects on gastrointestinal perfusion and coagulation cannot be excluded.
Comment in
- Vasopressin effect on pulmonary arterial pressure.
Chamorro C, Silva JA, Romera MA, Márquez J, Pardo C. Chamorro C, et al. Anesth Analg. 2002 Feb;94(2):479. doi: 10.1097/00000539-200202000-00059. Anesth Analg. 2002. PMID: 11812730 No abstract available.
Similar articles
- Cardiac performance during vasopressin infusion in postcardiotomy shock.
Dünser MW, Mayr AJ, Stallinger A, Ulmer H, Ritsch N, Knotzer H, Pajk W, Mutz NJ, Hasibeder WR. Dünser MW, et al. Intensive Care Med. 2002 Jun;28(6):746-51. doi: 10.1007/s00134-002-1265-y. Epub 2002 Apr 30. Intensive Care Med. 2002. PMID: 12107681 - Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.
Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, Bachetoni A, D'Alessandro M, Van Aken H, Pietropaoli P, Westphal M. Morelli A, et al. Crit Care. 2009;13(4):R130. doi: 10.1186/cc7990. Epub 2009 Aug 10. Crit Care. 2009. PMID: 19664253 Free PMC article. Clinical Trial. - Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study.
Dünser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Dünser MW, et al. Circulation. 2003 May 13;107(18):2313-9. doi: 10.1161/01.CIR.0000066692.71008.BB. Epub 2003 May 5. Circulation. 2003. PMID: 12732600 Clinical Trial. - [Arginine vasopressin in vasodilatory shock: a new therapy approach?].
Dünser M, Wenzel V, Mayr AJ, Hasibeder WR. Dünser M, et al. Anaesthesist. 2002 Aug;51(8):650-9; discussion 659-60. doi: 10.1007/s00101-002-0349-y. Anaesthesist. 2002. PMID: 12391525 Review. German. - Arginine vasopressin in 316 patients with advanced vasodilatory shock.
Luckner G, Dünser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Mayr AJ, Friesenecker B. Luckner G, et al. Crit Care Med. 2005 Nov;33(11):2659-66. doi: 10.1097/01.ccm.0000186749.34028.40. Crit Care Med. 2005. PMID: 16276194 Review.
Cited by
- Role of vasopressin in the management of septic shock.
Mutlu GM, Factor P. Mutlu GM, et al. Intensive Care Med. 2004 Jul;30(7):1276-91. doi: 10.1007/s00134-004-2283-8. Epub 2004 Apr 21. Intensive Care Med. 2004. PMID: 15103461 Review. - [Vasopressin and terlipressin in sepsis and systemic inflammatory response syndrome. Effects on microcirculation, oxygen transport, metabolism and organ function].
Ertmer C, Sielenkämper AW, van Aken H, Bone HG, Westphal M. Ertmer C, et al. Anaesthesist. 2005 Apr;54(4):346-56. doi: 10.1007/s00101-004-0796-8. Anaesthesist. 2005. PMID: 15625598 Review. German. - Vasopressin in Septic Shock; Assessment of Sepsis Biomarkers: A Randomized, Controlled Trial.
Barzegar E, Nouri M, Mousavi S, Ahmadi A, Mojtahedzadeh M. Barzegar E, et al. Indian J Crit Care Med. 2017 Sep;21(9):578-584. doi: 10.4103/ijccm.IJCCM_258_17. Indian J Crit Care Med. 2017. PMID: 28970657 Free PMC article. - Vasopressor hormones in shock-noradrenaline, vasopressin or angiotensin II: which one will make the race?
Dünser MW, Meier J. Dünser MW, et al. J Thorac Dis. 2017 Jul;9(7):1843-1847. doi: 10.21037/jtd.2017.06.127. J Thorac Dis. 2017. PMID: 28839980 Free PMC article. No abstract available. - The effect of pituitrin on postoperative outcomes in patients with pulmonary hypertension undergoing cardiac surgery: a study protocol for a randomized controlled trial.
Kong L, Lv M, Qiao CL, Sun XX, Du WY, Li Q. Kong L, et al. Front Cardiovasc Med. 2024 Jan 3;10:1269624. doi: 10.3389/fcvm.2023.1269624. eCollection 2023. Front Cardiovasc Med. 2024. PMID: 38235292 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous